CAMBRIDGE, Mass., October 24, 2007 – Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced the addition of two new executives joining the scientific and operational areas of the organization. Karen Ferrante, M.D., is the Senior Vice President of Clinical Development and Charles Reinhart is the Senior Vice President of Finance.
“We are excited to welcome Karen and Charles to the Millennium team,” said Deborah Dunsire, M.D., President and Chief Executive Officer, Millennium. “One of our greatest strengths is the ability to recruit and develop industry-leading talent. Recognized for providing leadership and strategic direction, these new senior staff members will contribute significantly to our mission of delivering valuable medicines to patients.”
As Senior Vice President of Clinical Development, Karen Ferrante brings more than 12 years of oncology clinical development expertise. Prior to joining Millennium, she served as Vice President of Global Research and Development and Oncology Therapeutic Area Clinical Leader at Pfizer, Inc. Previously, Karen was the Associate Director of Clinical Oncology at Bristol-Myers Squibb Company (BMS). During her tenure at Pfizer and BMS, Karen was involved in the development of cancer drugs, including Taxol®, Sutent® and Tarceva®. Karen earned a Bachelor of Science degree cum laude from Providence College and an M.D. from Georgetown University. She completed her medical residency and hematology/oncology fellowship at New England Deaconess Hospital, where she served as a staff physician.
Charles Reinhart, Senior Vice President of Finance, has more than 25 years of diverse financial experience, including 15 years in the healthcare and biopharmaceutical industries. For the past seven years, he served as Vice President of Finance, at Cephalon, Inc. During his tenure at Cephalon, Charles provided financial leadership in the areas of accounting, financial reporting, tax, treasury, financial analysis and planning, capital raising, and business development. He is a Certified Public Accountant. Charles graduated cum laude from Lehigh University with a Bachelor of Science degree in Accounting and earned an M.B.A. from The Wharton School, University of Pennsylvania.
About Millennium
Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. Millennium’s research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. Millennium’s website is www.millennium.com.
This press release contains “forward-looking statements,” including statements about the Company’s growth and development of products. Various important risks may cause the Company’s actual results to differ materially from the results indicated by these forward-looking statements, including: adverse results in its drug discovery and clinical development programs; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; the Company’s dependence upon strategic alliance partners to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company’s products; government and third-party reimbursement rates; the commercial success of VELCADE and INTEGRILIN® (eptifibatide) Injection; achieving revenue consistent with internal forecasts; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties the Company faces, see the reports it has filed with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
www.millennium.com.
